By: Karen Chen, PharmD Candidate c/o 2019 – Ibalizumab-uiyk (Trogarzo®) is specifically indicated for the treatment of human immunodeficiency virus type- 1 (HIV-1) infection in combination with other antiretroviral medications in heavily-treatment experienced adults with multidrug resistant HIV-1 infections who are failing their current antiretroviral regimen. Ibalizumab-uiyk is a CD4- directed post-attachment HIV-1 inhibitor that…

By: Shireen Farzadeh, PharmD Candidate c/o 2019 – Nivolumab (Opdivo®) is a monoclonal antibody that blocks programmed death receptor-1 (PD-1). PD-1 plays an important role in the immune checkpoint cascade. It is indicated for the treatment of melanoma, renal cell carcinoma, non-small cell and small cell lung cancer, squamous cell carcinoma of the head and…

By: Michael Lim, PharmD Candidate c/o 2020 – In an era of widespread pharmaceutical innovation, the rise of biological products is no surprise. Biosimilars – biological products that are highly similar to and have no clinically meaningful differences compared to reference products that are approved by the Food and Drug Administration (FDA) – have taken…